Hims Peptides+: What Launches, and the BPC-157 Plan
Hims says Peptides+ launches at the end of November with four products, and that it will make BPC-157 and TB-500 raw ingredients in Menlo Park later. Here is what was said, what it means, and what the evidence shows.
Build your own printable peptide tracker
A personalized injection log, weekly dosing schedule and dated calendar: your compounds filled in, ready to print. Free to build and preview; $5/month to unlock printing.
What Hims Said on the November 9 Call
Dudum said "the Peptides+ category is going to be coming to market end of this month," with "clinician-led treatment plans and access to regular blood testing." The first phase is sermorelin, glutathione, NAD+ and B12.
Okupe: "We plan to add BPC-157 and TB-500 when the regulatory environment permits." Dudum said they will be "manufactured and compounded in the U.S." No launch date or price was given.
Dudum said Hims "acquired and have integrated a peptide manufacturing facility in Menlo Park" and will be "manufacturing raw APIs" there for peptides like TB-500 and BPC-157. Raw API is the bulk powder a pharmacy compounds into a finished product.
Okupe said peptide revenue "is not expected to be material in the fourth quarter." On the same call Hims said Andrew Huberman had joined its Board of Directors.
What the Data Shows
What Launches First, and What Is the Evidence?
Hims named four products for the first phase of Peptides+. Two of them are peptides: sermorelin and glutathione (a tripeptide antioxidant). NAD+ is a coenzyme and B12 is a vitamin. Hims did not say which form or dose of each it will prescribe, so the evidence below is for the compound, not for the Hims product.
| Product | What it is | Best human evidence we found |
|---|---|---|
| Sermorelin | A 29-amino-acid analogue of growth hormone-releasing hormone (GHRH) that stimulates growth hormone release from the pituitary. | A 1999 drug review covers its use as a diagnostic test for growth hormone deficiency and, on limited data, once-daily injections that promoted growth in some children with idiopathic growth hormone deficiency. Flushing and injection-site pain were the most common side effects (PMID 18031173). The review does not cover adult wellness use. |
| Glutathione | The body's most abundant endogenous antioxidant, a three-amino-acid molecule. | In a 6-month randomized, placebo-controlled trial in 54 adults, oral glutathione at 1,000 mg/day raised levels 30-35% in red cells, plasma and lymphocytes; in most cases levels returned to baseline after a 1-month washout (PMID 24791752). |
| NAD+ | A coenzyme the body uses in energy metabolism and DNA repair, given in clinics by IV or injection. | A 2026 systematic review of 113 studies found no eligible outcome trials of IV or intramuscular NAD+ for anti-aging or wellness (PMID 41655607). In a 6-hour IV pilot, plasma NAD+ did not change for the first 2 hours (PMID 31572171). In a retrospective review, 500 mg NAD+ IV brought moderate to severe gut symptoms, raised heart rate and chest pressure during infusions (PMID 41704678). |
| Vitamin B12 | An essential vitamin, usually given as an injection or tablet for deficiency. | A 2018 Cochrane review of 3 trials (153 people) found low-quality evidence that oral and intramuscular B12 normalise serum B12 about equally in people who are deficient, with oral costing less (PMID 29543316). |
Launch list from the Hims Q3 2026 earnings call transcript, Nov 9, 2026. The NAD+ IV chart-review study (PMID 41704678) was run by authors employed by a commercial IV provider.
What Did Hims Actually Say About BPC-157 and TB-500?
Posts on X ran the Menlo Park quote as breaking news. The quote is real. The headlines tend to drop the timing and the conditions around it.
| What went viral on X | What the call and the rules say |
|---|---|
| "Hims will make its own BPC-157 and TB-500." | CEO Andrew Dudum said Hims will be "manufacturing raw APIs in our facilities in Menlo Park" for peptides like TB-500 and BPC-157, where he said raw-ingredient supply chains fall short of the quality Hims wants. Raw API (active pharmaceutical ingredient) is the bulk powder a pharmacy compounds from. It is not a finished product. |
| "BPC-157 is coming to Hims this month." | No. The end-of-November launch is sermorelin, glutathione, NAD+ and B12. CFO Yemi Okupe said Hims plans to add BPC-157 and TB-500 "when the regulatory environment permits." No date was given. |
| "Hims is the only US company with that kind of quality oversight." | That is the company's own description of itself, and we could not verify it. Federal law already sets a floor for every 503A pharmacy: each bulk drug substance must be made by an FDA-registered establishment and come with a valid certificate of analysis (21 U.S.C. 353a(b)(1)(A)). |
| "Made by Hims means FDA-approved." | No. Compounded drugs are not FDA-approved. The HHS policy covering BPC-157 and TB-500 is interim enforcement discretion while FDA rulemaking continues, and HHS says it is not binding (HHS Federal Register notice 2026-22192). |
Quotes from the Hims Q3 2026 earnings call transcript, Nov 9, 2026. Regulatory text from HHS Federal Register notice 2026-22192 and 21 U.S.C. 353a(b)(1)(A).
Key Takeaways
- Hims said on its November 9, 2026 earnings call that Peptides+ launches at the end of November with sermorelin, glutathione, NAD+ and B12.
- Hims plans to add BPC-157 and TB-500 "when the regulatory environment permits" and says it will make their raw API at its Menlo Park facility.
- Under 503A, every bulk drug substance must come from an FDA-registered establishment with a valid certificate of analysis, whoever makes it.
- HHS covers BPC-157 and TB-500 under an interim, non-binding enforcement discretion policy. Compounded drugs are not FDA-approved.
- A 2026 systematic review found three small uncontrolled human BPC-157 studies with 30 people in total and very low certainty (PMID 42885452).
- Oral glutathione raised body stores in a 6-month randomized trial (PMID 24791752); no eligible outcome trials have tested IV or intramuscular NAD+ for wellness (PMID 41655607).
- What Peptides+ will cost, or which states it will serve.
- When, or whether, Hims will offer BPC-157 and TB-500.
- Whether the Menlo Park facility will make API to a higher standard than other suppliers; Hims gave no testing data.
- Which form, dose and route Hims will prescribe for each first-phase product.
- Whether BPC-157 or TB-500 helps any musculoskeletal condition in people: no controlled human orthopaedic efficacy evidence exists (PMID 42937313).
- Long-term human safety for these peptides. A 2026 review calls rigorous human safety data for unapproved peptides scarce (PMID 41966639).
Frequently Asked Questions
When does Hims Peptides+ launch?
Hims CEO Andrew Dudum said on the November 9, 2026 earnings call that Peptides+ is "coming to market end of this month." The first phase includes sermorelin, glutathione, NAD+ and B12, with clinician-led treatment plans and access to regular blood testing. Hims has not published prices.
Will Hims sell BPC-157 and TB-500?
Hims says it plans to. CFO Yemi Okupe said it will add BPC-157 and TB-500 "when the regulatory environment permits," and Dudum said they will be manufactured and compounded in the U.S. No date or price was given, and neither peptide is in the late-November launch.
What does it mean that Hims will make raw API in Menlo Park?
Raw API is the bulk active ingredient, the powder a pharmacy compounds into a finished product. Dudum said Hims will make it for TB-500 and BPC-157 at a peptide manufacturing facility it acquired in Menlo Park, California, because he said existing supply chains fall short of the quality Hims wants.
Is Hims BPC-157 FDA-approved?
No. Compounded drugs are not FDA-approved. HHS has said it does not intend to take enforcement action against qualifying 503A compounding of six peptides, BPC-157 and TB-500 among them, while FDA rulemaking continues. HHS calls that policy interim and not binding.
Does NAD+ IV therapy work?
It is unproven for wellness. A 2026 systematic review of 113 studies found no eligible outcome trials of IV or intramuscular NAD+ for anti-aging or wellness (PMID 41655607). Oral precursors such as nicotinamide riboside raised NAD-related markers in trials, but effects on health outcomes were mixed or null.
BPC-157 + TB-500 for Laboratory Research
Swiss Chems publishes third-party HPLC COAs for selected products (vendor-published, a claim to verify). Deep-linked to the BPC-157 + TB-500 product page. Sold for laboratory research only, not for human use: the review cited below (PMID 42885452) concludes BPC-157 should not be used clinically in humans outside ethically approved, regulated clinical trials.
View BPC-157 + TB-500 at Swiss Chems →Affiliate links support HighPeptides at no extra cost.
Recommended Products
Support supplements and gear relevant to this protocol.
Affiliate links support HighPeptides at no extra cost.
Related HighPeptides Research
Peer-Reviewed References
67-page guide: protocols, dosing, sourcing. Everything in one place.
Get the guide: $19 (normally $29) → The Peptide Buyer’s Playbook ($19) All ebooks & guides →Educational purposes only. Not medical advice.
Compounded peptides are not FDA-approved. Company plans described here are forward-looking statements from Hims and may change.
Get the Free 2026 Peptide Protocol Stack
Twelve compounds across four pillars: metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.